After four years of follow-up, final pre-specified overall survival analysis from the pivotal phase III CLEAR/KEYNOTE-581 trial showed that Keytruda plus Lenvima maintained a clinically meaningful OS benefit versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma, reducing the risk of death by 21%.
Addition of the immunotherapy drug pembrolizumab (Keytruda) to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results of the SU2C-SARC032 clinical trial led by researchers from the University of Pittsburgh, UPMC, Duke University, and Princess Margaret Cancer Centre.
